Sodium selenate(Sodium selenate) - 药物靶点：Akt-1 x PI3K family x PP2A_在研适应症：额颞痴呆，进行性核上性麻痹，阿尔茨海默症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

Akt-1 x PI3K family x PP2A

作用机制

Akt-1抑制剂(丝氨酸/苏氨酸蛋白激酶AKT抑制剂)、PP2A刺激剂(蛋白质磷酸酶2A刺激剂)、Phosphatidylinositol 3-kinase family inhibitors

治疗领域

神经系统疾病内分泌与代谢疾病眼部疾病+ [1]

在研适应症

额颞痴呆进行性核上性麻痹阿尔茨海默症+ [1]

非在研适应症-

原研机构

Velacor Therapeutics Pty Ltd.

在研机构

Monash University

University of MelbourneJSW Lifesciences GmbH

非在研机构

Velacor Therapeutics Pty Ltd.

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (欧盟)

登录后查看时间轴

结构

分子式H2NaO4Se

InChIKeyPRKRTJSKTGAVMH-UHFFFAOYSA-N

CAS号13410-01-0

查看全部结构式(2)

关联

7

项与 Sodium selenate 相关的临床试验

ACTRN12623000446662 / Not yet recruiting临床2期

A Phase 2 Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Chronic Drug-resistant Temporal Lobe Epilepsy

开始日期2023-10-01

申办/合作机构

Alfred Health

ACTRN12620000236998 / Recruiting临床2期

A Phase 2b Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Possible Behavioural Variant Fronto-temporal Dementia

开始日期2021-08-17

申办/合作机构

Alfred Health

ACTRN12620001254987 / Recruiting临床2期

A Phase 2 Randomised Controlled Trial of Sodium Selenate as aDisease Modifying Treatment for Probable Progressive SupranuclearPalsy

开始日期2021-07-29

申办/合作机构

Alfred Health

100 项与 Sodium selenate 相关的临床结果

登录后查看更多信息

100 项与 Sodium selenate 相关的转化医学

登录后查看更多信息

100 项与 Sodium selenate 相关的专利（医药）

登录后查看更多信息

805

项与 Sodium selenate 相关的文献（医药）

2024-12-01·Pharmacology Research & Perspectives

Pharmacokinetics and brain uptake of sodium selenate and selenium in naïve rats and a lateral fluid percussion injury rat model

Article

作者: Ali, Idrish ; Moshe ́, Solomon L. ; Liu, Wei ; Cloyd, James C. ; Casillas‐Espinosa, Pablo M. ; O'Brien, Terence J. ; Jones, Nigel C. ; Li, Chenxu ; Mishra, Usha ; Silva, Juliana ; Coles, Lisa D. ; Yamakawa, Glenn ; Hudson, Matt ; Chi, Tina ; Saletti, Patricia Grandizoli ; Galanopoulou, Aristea S. ; Shultz, Sandy R.

AbstractPost‐traumatic epilepsy (PTE) is a life‐long complication of traumatic brain injury (TBI). The development of PTE is associated with neurological morbidity and increases the risk of mortality. An aim of EpiBioS4Rx (Epilepsy Bioinformatics Study for Antiepileptogenic Therapy) was to test potential therapies to prevent the development of PTE in the lateral fluid percussion injury (LFPI) rat model of TBI, in which rats were subjected to injury at the left parietal cortex. Sodium selenate has been reported to be antiepileptogenic post‐TBI in rodent models by activating protein phosphatase 2A and reducing phosphorylated tau (p‐tau) protein. We aimed to characterize the pharmacokinetics (PK) and brain uptake of sodium selenate using naïve control and LFPI rats. Rats received either a single bolus dose or a single bolus dose followed by a 7‐day subcutaneous minipump infusion of sodium selenate. Sodium selenate and selenium concentrations in plasma and brain were analyzed and used for PK estimation and brain exposure assessment. Selenium concentrations rapidly increased after sodium selenate administration, demonstrating biotransformation from sodium selenate to selenium. Sodium selenate and selenium PK parameters were estimated using non‐compartmental analysis. Sodium selenate clearance (CL/F) and volume of distribution (Vd/F) varied by dose and route of administration, suggesting differences in bioavailability and nonlinear pharmacokinetics at the doses tested. Brain‐to‐plasma partition coefficients (AUCbrain/AUCplasma) for sodium selenate and selenium were found to be 0.7–1.3 and 0.1–0.3 following single‐dose injection, respectively, indicating active transport of sodium selenate across the blood–brain barrier (BBB).

2024-10-01·Environmental Pollution

Selenate simultaneously alleviated cadmium and arsenic accumulation in rice (Oryza sativa L.) via regulating transport genes

Article

作者: Tao, Yanjin ; Wan, Yanan ; Huang, Siyu ; Fan, Yu ; Wang, Qi ; Li, Huafen ; Liu, Zhe ; Qi, Hao ; Wang, Qiqi

Cadmium (Cd) and arsenic (As) have contrasting biogeochemical behaviors in paddy soil, which posed an obstacle for reducing their accumulation in rice (Oryza sativa L.) simultaneously. In this study, selenate exhibited a more effective ability than selenite on simultaneous alleviation of Cd and As accumulation in rice under Cd-As co-exposure, and the mechanisms need to be further investigated. The results showed that selenate significantly decreased the root Cd and As contents by 59%-83% and 43%-72% compared to Cd-As compound exposure, respectively. Correspondingly, it significantly down-regulated the expression of uptake-related genes OsNramp5 (87.1%) and OsLsi1 (95.5%) in rice roots. Decreases in Cd (64.5%) and As (16.2%) contents in shoots were also found after selenate addition. Moreover, selenate may promoted the reduction of As(V) to As(Ⅲ) and As(III) efflux to the external medium, resulting in decreased As accumulation and As(Ⅲ) proportion in rice shoots and roots. In addition, selenate could promote the binding of Cd (by 14%-24%) and As (by 9%-15%) in the cell wall, and significantly reduced the oxidative stress by elevating levels of antioxidant enzymes (by 10%-105%) and thiol compounds (by 6%-210%). Additionally, selenate significantly down-regulated the expression of OsNramp1 (49.3%) and OsLsi2 (82.1%) associated with Cd and As transport in rice. These findings suggest selenate has the potential to be an effective material for the simultaneous reduction of Cd and As accumulation in rice under Cd-As co-contamination.

2024-09-01·Journal of Environmental Sciences

Effect of inorganic arsenic in paddy soil on the migration and transformation of selenium species in rice plants

Article

作者: Wang, Ze ; Zhu, Xi ; Li, Hong ; Fu, Fengfu ; Wang, Kaiteng ; Yang, Guidi ; Ying, Kaiyang ; Qu, Can ; Wu, Yongchen ; Pokhrel, Ganga Raj

Selenium (Se) in paddy rice is one of the significant sources of human Se nutrition. However, the effect of arsenic (As) pollution in soil on the translocation of Se species in rice plants is unclear. In this research, a pot experiment was designed to examine the effect of the addition of 50 mg As/kg soil as arsenite or arsenate on the migration of Se species from soil to indica Minghui 63 and Luyoumingzhan. The results showed that the antagonism between inorganic As and Se was closely related to the rice cultivar and Se oxidation state in soil. Relative to the standalone selenate treatment, arsenite significantly (p < 0.05) decreased the accumulation of selenocystine, selenomethionine and selenate in the roots, stems, sheaths, leaves, brans and kernels of both cultivars by 21.4%-100.0%, 40.0%-100.0%, 41.0%-100%, 5.4%-96.3%, 11.3%-100.0% and 26.2%-39.7% respectively, except for selenocystine in the kernels of indica Minghui 63 and selenomethionine in the leaves of indica Minghui 63 and the stems of indica Luyoumingzhan. Arsenate also decreased (p < 0.05) the accumulation of selenocystine, selenomethionine and selenate in the roots, stems, brans and kernels of both cultivars by 34.9%-100.0%, 30.2%-100.0%, 11.3%-100.0% and 5.6%-39.6% respectively, except for selenate in the stems of indica Minghui 63. However, relative to the standalone selenite treatment, arsenite and arsenate decreased (p < 0.05) the accumulation of selenocystine, selenomethionine and selenite only in the roots of indica Minghui 63 by 45.5%-100.0%. Our results suggested that arsenite and arsenate had better antagonism toward Se species in selenate-added soil than that in selenite-added soil; moreover, arsenite had a higher inhibiting effect on the accumulation of Se species than arsenate.

100 项与 Sodium selenate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	A12CE01	DB11068

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床2期	澳大利亚	Velacor Therapeutics Pty Ltd.	-
额颞痴呆	临床前	澳大利亚	Monash University	2024-10-11
进行性核上性麻痹	临床前	澳大利亚	Monash University	2023-10-13
癫痫	临床前	澳大利亚	Monash University	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AAIC2021	N/A	痴呆	12	Sodium selenate 15mg tds	願鏇繭積淵餘齋選範醖(鏇網齋壓醖構鏇築築鑰) = n=3 築憲鏇範艱範蓋鹹壓範 (蓋夢廠簾網網鹹憲獵鹹 ) 更多	-	2021-12-31
AAIC2020	N/A	额颞痴呆	15	Sodium selenate 15mg	(製鹹繭繭餘鏇齋艱夢選) = n=4 膚廠膚鏇築衊襯積夢窪 (壓壓淵艱壓選餘獵積遞 ) 更多	-	2020-12-07